Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching-I Huang

Showing results (81-90 of 156) with videos related to

Pageof 16
Sort By:
The Kaohsiung Journal of Medical Sciences|September 2, 2023
Unawareness of hepatitis B infection and lack of surveillance are associated with severity of hepatocellular carcinomaKuan-I Lee, Po-Cheng Liang, Po-Yau Hsu, et al.
Oncotarget|March 16, 2018
The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infectionChia-Yen Dai, Yi-Shan Tsai, Wen-Wen Chou, et al.
The Kaohsiung Journal of Medical Sciences|October 6, 2020
Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancyMing-Lun Yeh, Hsing-Tao Kuo, Ching-I Huang, et al.
Medicine|October 27, 2015
Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized StudyMing-Lun Yeh, Ming-Yen Hsieh, Ching-I Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 12, 2017
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in TaiwanMeng-Hsuan Hsieh, Ming-Lun Yeh, Tung-Hung Su, et al.
Viruses|November 11, 2022
Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVRPo-Yao Hsu, Po-Cheng Liang, Ching-I Huang, et al.
The Kaohsiung Journal of Medical Sciences|February 16, 2024
Third vaccine boosters and anti-S-IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinomaChih-Wen Wang, Chung-Feng Huang, Tyng-Yuan Jang, et al.
Journal of Hepatology|November 9, 2010
The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trialJee-Fu Huang, Ming-Lung Yu, Chung-Feng Huang, et al.
Journal of Gastroenterology and Hepatology|August 3, 2019
Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevirChung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 23, 2015
MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replicationWen-Wen Chou, Chung-Feng Huang, Ming-Lun Yeh, et al.
Pageof 16

Showing results (81-90 of 156) with videos related to

Sort By:
Pageof 16
The Kaohsiung Journal of Medical Sciences|September 2, 2023
Unawareness of hepatitis B infection and lack of surveillance are associated with severity of hepatocellular carcinomaKuan-I Lee, Po-Cheng Liang, Po-Yau Hsu, et al.
Oncotarget|March 16, 2018
The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infectionChia-Yen Dai, Yi-Shan Tsai, Wen-Wen Chou, et al.
The Kaohsiung Journal of Medical Sciences|October 6, 2020
Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancyMing-Lun Yeh, Hsing-Tao Kuo, Ching-I Huang, et al.
Medicine|October 27, 2015
Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized StudyMing-Lun Yeh, Ming-Yen Hsieh, Ching-I Huang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|July 12, 2017
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in TaiwanMeng-Hsuan Hsieh, Ming-Lun Yeh, Tung-Hung Su, et al.
Viruses|November 11, 2022
Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVRPo-Yao Hsu, Po-Cheng Liang, Ching-I Huang, et al.
The Kaohsiung Journal of Medical Sciences|February 16, 2024
Third vaccine boosters and anti-S-IgG levels: A comparison of homologous and heterologous responses and poor immunogenicity in hepatocellular carcinomaChih-Wen Wang, Chung-Feng Huang, Tyng-Yuan Jang, et al.
Journal of Hepatology|November 9, 2010
The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trialJee-Fu Huang, Ming-Lung Yu, Chung-Feng Huang, et al.
Journal of Gastroenterology and Hepatology|August 3, 2019
Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevirChung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 23, 2015
MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replicationWen-Wen Chou, Chung-Feng Huang, Ming-Lun Yeh, et al.
Pageof 16